Press releases 2022
September 28, 2022
Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License
April 19, 2022
Quest PharmaTech Provides Corporate Update
Press releases 2021
September 1, 2021
OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer
July 7, 2021
Quest PharmaTech Announces Results from AGM
June 1, 2021
Quest PharmaTech Announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists
March 26, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.
February 2, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.
January 5, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.
Press releases 2020
November 9, 2020
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company’s Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer
June 4, 2020
Quest Provides Corporate Update
May 29, 2020
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings
April 22, 2020
OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer
March 24, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company’s Lead Investigational Drug in Frontline Ovarian Cancer
March 13, 2020
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.
Press releases 2019
September 25, 2019
OncoQuest Receives “Notice of Allowance” for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients
January 29, 2019
Quest PharmaTech Announces Results from AGM
January 25, 2019
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer
Press releases 2018
December 19, 2018
Quest PharmaTech Adopts Amendment to By-laws Requiring Advance Notice of Nomination of Directors
December 3, 2018
Quest PharmaTech Announces Adoption of Shareholder Rights Plan
November 28, 2018
Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.
July 20, 2018
Madenco Biosciences Announces Strategic Decision to Drop Consumer Health Products and Focus on Pharmaceutical Product Development
June 1, 2018
Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting
May 14, 2018
Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer
February 12, 2018
OncoQuest to Present at BIO CEO & Investor Conference
February 6, 2018
OncoQuest Completes US $6 Million Private Placement
January 3, 2018
Madenco Biosciences Announces Licensing Agreement for Patented EGF Wound Healing Technology
